This information is particularly relevant to understand both the time windows of efficacy for potential treatments and the selectivity/sensitivity to TDP-43 dysregulation of the neural circuits underlying the clinical phenotypes displayed by FTD/ALS patients. This evidence concerns the gene TARDBP and frontotemporal dementia.